Ajanta Pharma Share Price

Ajanta Pharma Share Price

NSE: AJANTPHARM
|
Pharmaceuticals
|
S Cap
â‚ą 3,529.50
+â‚ą64.70 (1.87%)
1D
Last updated 07 Sep, 2026, 12:22 IST

Ajanta Pharma Share Price Today

As of 7 Sep 2026, Ajanta Pharma share price is â‚ą3,529.50. The stock opened at â‚ą3,445.00, compared to its previous close of â‚ą3,464.80. During today's trading session, Ajanta Pharma share price moved in the range of â‚ą3,438.00 to â‚ą3,539.00, with an average price of â‚ą3,488.50 for the day. Looking at its last 52-week, the stock has touched a low of â‚ą2,329.90 and a high of â‚ą3,796.00. On the performance front, Ajanta Pharma share price has increased by 18.81% over the last six months and is up 33.23% on a year-on-year basis.

â‚ą3,438.00
1.87% up today
â‚ą3,539.00
1D LOW
1D HIGH

Ajanta Pharma Returns Calculator

Circuit
L
H
â‚ą2,771.90
â‚ą4,157.70
52-week
L
H
â‚ą2,329.90
â‚ą3,796.00

About Ajanta Pharma

Ajanta Pharma Share Price
ISIN
INE031B01049
Sector Market Cap
â‚ą 43,291.4 Cr

Ajanta Pharma Limited is an India-based specialty pharmaceutical company. It provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. It is focused on branded generic businesses across India, Asia, and Africa. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its business also consists of two verticals: the United States generics and the institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). Its cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin. Its subsidiaries include Ajanta Pharma (Mauritius) Limited, Ajanta Pharma USA Inc., Ajanta Pharma Philippines Inc., and Ajanta Pharma Nigeria Limited.

Ajanta Pharma Financial Highlights

  • Revenue: Ajanta Pharma reported revenue of â‚ą5,624.93 crore in FY26 vs â‚ą4,742.60 crore in FY25. It showed an increase of 18.60% on a yearly basis.
  • Operating Profit: Ajanta Pharma reported an operating profit of â‚ą1,377.65 crore in FY26 vs â‚ą1,189.16 crore in FY25. It showed an increase of 15.85% on a year-on-year basis.
  • Net Profit: Ajanta Pharma reported a net profit of â‚ą1,056.00 crore in FY26 vs â‚ą920.39 crore in FY25. It showed an increase of 14.73% on a yearly basis.

Ajanta Pharma Quarterly Result Highlights

  • Ajanta Pharma reported revenue of â‚ą1,696.86 crore in Jun 2026, compared with â‚ą1,483.07 crore in Mar 2026, representing an increase of 14.42% on a quarter-on-quarter (QoQ) basis.
  • Ajanta Pharma reported an operating profit of â‚ą446.80 crore in Jun 2026, compared with â‚ą347.11 crore in Mar 2026, representing an increase of 28.72% on a quarter-on-quarter (QoQ) basis.
  • Ajanta Pharma reported a profit of â‚ą334.22 crore in Jun 2026, compared with â‚ą266.70 crore in Mar 2026, reflecting an increase of 25.32% on a QoQ basis.
  • The earnings per share (EPS) of Ajanta Pharma stood at â‚ą84.53 during Jun 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Know more
Promoters
63.48%
FII
7.68%
Other DII
3.70%
Retail and other
7.03%
Mutual funds
18.10%
Foreign Institutional Investor (FII)
FII shareholding by period
Sep 20258.53%
Dec 20257.98%
Mar 20268.26%
Jun 20267.68%
Mkt Cap Cr
43,291.40
P/E
38.15
P/B
9.56
ROE
23.33%
D/E
0.01
ROCE
29.09%
Div. Yield
0.81%
EPS(TTM)
75.79
Turnover
0.96
EV/EBITDA
25.81
Net Margin
19.54%
Op. Margin
28.94%
ROA
18.44%
Quick Ratio
2.55
Curr. Ratio
3.52
Based on fundamentals, this stock's
Step 5 of 5
Performance
Excellent
Ajanta Pharma outperforming all market indices
Step 1 of 5
Valuation
Overvalued
Ajanta Pharma appears overvalued compared to its peers
Step 5 of 5
Earnings
Excellent
Ajanta Pharma revenue, operating profit and net profit are growing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Sun Pharmaceutical Industries4,55,634.0037.605.4513.74%0.6117.33%93.240.84%0.4810.90
Divis Laboratories2,41,576.0082.5914.4115.32%0.0019.56%629.490.33%0.5598.19
Torrent Pharmaceuticals1,84,478.0085.5721.9425.49%1.6913.85%222.760.70%0.4958.70
Cipla1,11,888.0033.343.2511.27%0.0014.95%423.360.94%0.4543.52
Zydus Lifesciences1,11,820.0024.354.1218.59%0.3117.35%237.300.09%0.3335.38
Laurus Labs99,417.5091.1818.7616.77%0.4016.14%97.200.11%0.6713.72
Lupin96,528.8017.394.3023.76%0.0424.88%659.000.85%0.57129.18
Dr. Reddy's Laboratories96,322.1030.262.5311.07%0.1812.54%377.950.69%0.4138.68
Mankind Pharma96,179.6046.525.9011.74%0.3413.13%396.980.04%0.4449.37
Aurobindo Pharma95,127.2025.642.519.25%0.1911.76%394.820.24%0.3841.58

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

Ajanta Pharma Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenueâ‚ą5,452.86â‚ą4,648.10â‚ą4,208.71â‚ą3,742.64
Other Incomeâ‚ą172.07â‚ą94.50â‚ą84.60â‚ą98.64
Total Revenueâ‚ą5,624.93â‚ą4,742.60â‚ą4,293.31â‚ą3,841.28
Total Expensesâ‚ą4,247.28â‚ą3,553.44â‚ą3,179.38â‚ą3,096.03
Profit Before Taxâ‚ą1,377.65â‚ą1,189.16â‚ą1,113.93â‚ą745.25
Taxâ‚ą321.65â‚ą268.77â‚ą297.76â‚ą157.27
Profit After Taxâ‚ą1,056.00â‚ą920.39â‚ą816.17â‚ą587.98
EPS - Basicâ‚ą84.53â‚ą73.56â‚ą64.82â‚ą45.89
EPS - Dilutedâ‚ą84.51â‚ą73.53â‚ą64.77â‚ą45.89

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before taxâ‚ą1,377.65â‚ą1,189.16â‚ą1,113.93â‚ą745.25
Income before WC changesâ‚ą1,541.11â‚ą1,301.27â‚ą1,196.96â‚ą876.55
Change in Assets-â‚ą780.61â‚ą31.26-â‚ą230.57-â‚ą3.45
Change in Liabilitiesâ‚ą127.68â‚ą147.67â‚ą130.81â‚ą70.30
Change in WC-â‚ą652.93â‚ą178.93-â‚ą99.76â‚ą66.85
Cash flow from Operationsâ‚ą529.19â‚ą1,157.23â‚ą785.07â‚ą792.11
Cash flow from Investing-â‚ą428.92-â‚ą376.52â‚ą65.39-â‚ą559.60
Cash flow from Financing-â‚ą167.92-â‚ą733.41-â‚ą1,051.06-â‚ą108.20
Total Cash Flow-â‚ą67.65â‚ą47.30-â‚ą200.60â‚ą124.31
Cash (Start of the year)â‚ą175.12â‚ą129.49â‚ą329.83â‚ą206.36
Cash (End of the year)â‚ą107.47â‚ą176.79â‚ą129.23â‚ą330.67

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assetsâ‚ą2,419.41â‚ą2,171.92â‚ą1,907.47â‚ą1,845.02
Current Assetsâ‚ą3,735.43â‚ą2,843.03â‚ą2,730.92â‚ą2,834.00
Total Assetsâ‚ą6,154.84â‚ą5,014.95â‚ą4,638.39â‚ą4,679.02
Current Liabilitiesâ‚ą1,415.75â‚ą996.10â‚ą895.76â‚ą1,139.28
Net Current Assetâ‚ą2,319.68â‚ą1,846.93â‚ą1,835.16â‚ą1,694.72
Non-Current Liabilitiesâ‚ą212.00â‚ą228.56â‚ą175.27â‚ą151.75
Equity Capitalâ‚ą4,527.09â‚ą3,790.29â‚ą3,567.36â‚ą3,387.99
Total Equity & Liabilitiesâ‚ą6,154.84â‚ą5,014.95â‚ą4,638.39â‚ą4,679.02

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenueâ‚ą4,845.92â‚ą4,322.04â‚ą3,971.12â‚ą3,411.27
Other Incomeâ‚ą204.40â‚ą119.87â‚ą116.48â‚ą132.75
Total Revenueâ‚ą5,050.32â‚ą4,441.91â‚ą4,087.60â‚ą3,544.02
Total Expensesâ‚ą3,819.29â‚ą3,261.85â‚ą2,990.65â‚ą2,844.17
Profit Before Taxâ‚ą1,231.03â‚ą1,180.06â‚ą1,096.95â‚ą699.85
Taxâ‚ą284.21â‚ą263.17â‚ą289.71â‚ą141.13
Profit After Taxâ‚ą946.82â‚ą916.89â‚ą807.24â‚ą558.72
EPS - Basicâ‚ą75.79â‚ą73.28â‚ą64.11â‚ą43.61
EPS - Dilutedâ‚ą75.78â‚ą73.25â‚ą64.06â‚ą43.61

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before taxâ‚ą1,231.03â‚ą1,180.06â‚ą1,096.95â‚ą699.85
Income before WC changesâ‚ą1,340.16â‚ą1,249.44â‚ą1,146.26â‚ą779.19
Change in Assets-â‚ą319.20-â‚ą42.65-â‚ą261.95â‚ą43.80
Change in Liabilitiesâ‚ą75.93â‚ą128.84â‚ą103.32â‚ą38.86
Change in WC-â‚ą243.27â‚ą86.19-â‚ą158.63â‚ą82.66
Cash flow from Operationsâ‚ą803.83â‚ą1,053.80â‚ą735.35â‚ą736.29
Cash flow from Investing-â‚ą399.56-â‚ą349.60â‚ą105.02-â‚ą501.31
Cash flow from Financing-â‚ą359.62-â‚ą715.71-â‚ą1,047.70-â‚ą105.12
Total Cash Flowâ‚ą44.65-â‚ą11.51-â‚ą207.33â‚ą129.86
Cash (Start of the year)â‚ą48.60â‚ą61.78â‚ą268.85â‚ą139.83
Cash (End of the year)â‚ą93.25â‚ą50.27â‚ą61.52â‚ą269.69

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assetsâ‚ą2,198.06â‚ą1,978.19â‚ą1,775.77â‚ą1,753.60
Current Assetsâ‚ą3,118.66â‚ą2,576.06â‚ą2,441.67â‚ą2,551.19
Total Assetsâ‚ą5,316.72â‚ą4,554.25â‚ą4,217.44â‚ą4,304.79
Current Liabilitiesâ‚ą891.03â‚ą710.72â‚ą629.70â‚ą907.84
Net Current Assetâ‚ą2,227.63â‚ą1,865.34â‚ą1,811.97â‚ą1,643.35
Non-Current Liabilitiesâ‚ą202.16â‚ą218.22â‚ą174.17â‚ą150.50
Equity Capitalâ‚ą4,223.53â‚ą3,625.31â‚ą3,413.57â‚ą3,246.45
Total Equity & Liabilitiesâ‚ą5,316.72â‚ą4,554.25â‚ą4,217.44â‚ą4,304.79
* All values are in INR Crore
Qty
Bid
1
3529.6
5
3529.4
2
3529.1
2
3529
2
3528.9
Ask
Qty
3531
82
3531.7
3
3531.9
1
3532.1
2
3532.7
1
Bid Total: 12
Ask Total: 89
Buy orders: 12%
Sell orders: 88%
Bearish
1
Neutral
3
Bullish
4
Slightly Bullish
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
43.71
Neutral
ATR (14)
102.46
Neutral
STOCH(9,6)
16.51
Bullish
STOCH RSI (14)
0
Bullish
ADX(9)
16.83
Bullish
UO(9)
41.24
Neutral
ROC(12)
-6.3
Bearish
WillR(14)
-89.27
Bullish
Period
Simple value
Exponential vaue
5D
3514.86
3506.35
10D
3536.15
3533.13
20D
3581.2
3540.28
50D
3480.1
3453.59
100D
3245.51
3302.03
Volume trend — traded volume by day
7 Sep0L
4 Sep0L
3 Sep0L
2 Sep0L
1 Sep0L
31 Aug0L
Average0L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks
Ajanta Pharma Share Price
Ajanta Pharma
Pharmaceuticals
Add Stock
Add Another

Ajanta Pharma Share Price FAQs

Ajanta Pharma share price data is sourced from NSE/BSE and may be delayed. It is displayed for informational purposes only and does not constitute investment advice or a recommendation to buy or sell.

Trusted by 2 Crore+ Indians for their wealth-building needs. SEBI Registered Broker. SEBI Reg No. INZ000315837